ImmunoTargets and Therapy · 2020 · 11 citations · 48 references
PharmacyImmunologyInfectious DiseasesAntibody EngineeringImmunology Of Infectious DiseasesMonoclonal AntibodiesAntibody CharacterizationAntibody DiscoveryDiagnostic Antibody ApplicationsDiagnostic Antibody DesignDiagnostic Monoclonal AntibodiesTherapeutic Monoclonal AntibodiesAntibodiesAntibody Therapeutic EfficacyAntigen-specific Antibody DiscoveryBacterial AntibodiesDetection AntibodiesHuman Antibody LibrariesPhage Display Library ConstructionPhage Display Library Generation
Background: Yersinia pestis is a category A infective agent that causes bubonic, septicemic, and pneumonic plague. Notably, the acquisition of antimicrobial or multidrug resistance through natural or purposed means qualifies Y. pestis as a potential biothreat agent. Therefore, high-quality antibodies designed for accurate and sensitive Y. pestis diagnostics, and therapeutics potentiating or replacing traditional antibiotics are of utmost need for national security and public health preparedness. Methods: Here, we describe a set of human monoclonal immunoglobulins (IgG1s) targeting Y. pestis fraction 1 (F1) antigen, previously derived from in vitro evolution of a phage-display library of single-chain antibodies (scFv). We extensively characterized these antibodies and their effect on bacterial and mammalian cells via: ELISA, flow cytometry, mass spectrometry, spectroscopy, and various metabolic assays. Results: Two of our anti-F1 IgG (αF1Ig 2 and αF1Ig 8) stood out for high production yield, specificity, and stability. These two antibodies were additionally attractive in that they displayed picomolar affinity, did not compete when binding Y. pestis , and retained immunoreactivity upon chemical derivatization. Most importantly, these antibodies detected < 1,000 Y. pestis cells in sandwich ELISA, did not harm respiratory epithelial cells, induced Y. pestis agglutination at low concentration (350 nM), and caused apparent reduction in cell growth when radiolabeled at a nonagglutinating concentration (34 nM). Conclusion: These antibodies are amenable to the development of accurate and sensitive diagnostics and immuno/radioimmunotherapeutics. Keywords: immunodiagnostic, radioimmunotherapy, RIT, immunotherapy, radiolabeling, immunoantibiotic, lateral flow assay, LFA
48
Brad Spellberg, R. Guidos, David N. Gilbert et al. · Clinical Infectious Diseases · 2007 · 1.7K citations · Full text
Beyond natural antibodies: the power of in vitro display technologies
Andrew Bradbury, Sachdev S. Sidhu, Stefan Dübel et al. · Nature Biotechnology · 2011 · 555 citations
Pharmacy, Biotechnology, Immunology +11